Methodology and process of developing the S3 guideline for prostate cancer

被引:0
|
作者
Nothacker, M. [1 ]
Roellig, C. [1 ,2 ]
Woeckel, A. [4 ]
Kopp, I. [3 ]
Ollenschlaeger, G. [1 ]
Weinbrenner, S. [1 ]
机构
[1] Arztliches Zentrum Qualitat Med, Bereich Evidenzbasierte Med & Leitlinien, D-10623 Berlin, Germany
[2] Univ Klinikum TU Dresden, Med Klin & Poliklin 1, Dresden, Germany
[3] Arbeitsgemeinschaft Wissensch Med Fachgesell, Dusseldorf, Germany
[4] Univ Klin Ulm, Klin Gynakol & Geburtshilfe, Ulm, Germany
来源
UROLOGE | 2010年 / 49卷 / 02期
关键词
Guideline; Evidence-based medicine; Consensus; Prostate cancer; Treatment; UPDATE;
D O I
10.1007/s00120-010-2233-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Despite the high incidence of prostate cancer and a variability of care due to different options for primary therapy, a comprehensive German clinical guideline has been missing up to now. Therefore, in 2005 the German Society for Urology initiated the development of a multidisciplinary and evidence-based S3 guideline for the early detection, diagnosis, and treatment of the different clinical manifestations of prostate cancer. There were 76 experts from 10 different medical societies and organizations including a patient organization involved in the development process. A total of 42 key questions were addressed. As a result of systematic literature searches and formal consensus processes, 170 recommendations and 42 statements were made. This article describes the objectives and the process of development of the guideline focusing on the cooperation between clinical and methodological experts as well as on the evidence and consensus basis of the recommendations.
引用
收藏
页码:173 / +
页数:6
相关论文
共 50 条
  • [1] Methodik und Entwicklungsprozess der S3-Leitlinie zum ProstatakarzinomMethodology and process of developing the S3 guideline for prostate cancer
    M. Nothacker
    C. Röllig
    A. Wöckel
    I. Kopp
    G. Ollenschläger
    S. Weinbrenner
    Der Urologe, 2010, 49 : 173 - 180
  • [3] Risks and prevention of prostate cancer - Commentary on the new S3 guideline
    Schmitz-Draeger, B. J.
    Bismarck, E.
    Luemmen, G.
    UROLOGE, 2010, 49 (02): : 233 - 237
  • [4] The German S3 Guideline Prostate Cancer Aspects for the Radiation Oncologist
    Wenz, Frederik
    Martin, Thomas
    Boehmer, Dirk
    Martens, Stefan
    Sedlmayer, Felix
    Wirth, Manfred
    Miller, Kurt
    Heidenreich, Axel
    Schrader, Mark
    Hinkelbein, Wolfgang
    Wiegel, Thomas
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (10) : 531 - 534
  • [5] S3 guideline on cervical cancer
    Fehm, Tanja
    Mallmann, Peter
    GYNAKOLOGE, 2019, 52 (08): : 568 - 569
  • [6] New S3 Guideline Melanoma - Milestones and Methodology
    Pflugfelder, A.
    Kochs, C.
    Follmann, M.
    Schadendorf, D.
    Garbe, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 3 - 3
  • [7] The S3 Guideline Exocrine Pancreatic Cancer
    Seufferlein, Thomas
    Adler, Guido
    MEDIZINISCHE KLINIK, 2009, 104 (11) : 869 - 874
  • [8] Esophageal Cancer S3 Guideline updated
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (12) : 737 - 738
  • [9] New S3 guideline prostate cancer 2021 (version 6.2)-What has changed in advanced prostate cancer?
    Thomas, C.
    Schrader, A. J.
    UROLOGIE, 2023, 62 (02): : 171 - 175
  • [10] Radiation therapy for prostate cancer in the new S3 guideline - Part 1: localized and locally advanced prostate cancer
    Boehmer, D.
    Wenz, F.
    Martin, T.
    Sedlmayr, F.
    Hinkelbein, W.
    Wiegel, T.
    UROLOGE, 2010, 49 (02): : 211 - 215